Loading…
← CockpitCompetitor Analysis › 468530.KS PROTEINA Co., Ltd.Open in the cockpit ↗

PROTEINA Co., Ltd.468530.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Medical Specialties
Momentum leader 96
Mkt cap
$460M
US dollars, full cap
Free float
55%
of shares outstanding
$/day
$9.98M
20-day average traded
P/B
26.75×
price to book
ROE
-68.1%
delivered
Implied ROE
70.0%
what the price asks
Close · KRW₩53,600
1D+7.6%
1W-5.5%
1M+24.9%
3M+42.5%
6M+5.1%
YTD-51.5%
1Y-16.4%
ATR %12.7%
52w lowhigh55.4% off high

What PROTEINA does

No business profile yet.

PROTEINA at a glance

Size PROTEINA (468530.KS) is a South Korea Health Care company (Medical Specialties) with a market value of $460M, the 364th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩53,600 on 18 Nov 2026.

Performance Over six months the shares gained 5.1%, against -16.2% for the median peer and -37.2% for the South Korea market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue fell 59.5% over the last twelve months (peer median +3.9%); the operating margin is -1,178.2% (peer median 6.1%).

Valuation It trades at 26.75× book value against a peer median of 2.04× (most expensive of 21).

Price implies The share price implies a return on equity of about 70.0%; PROTEINA delivers -68.1%, so the price asks more than the business earns today.

Relative performance

5010021 May 202621 Aug 202618 Nov 2026468530.KS 110Peer median 85
Six months, rebased to 100: PROTEINA against the median of its 20 peers (local-currency closes).

PROTEINA financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩1.44B₩2.95B₩2.30B₩578M₩466M
Revenue growth—+28%+298%+24%—
Gross profit-₩502M₩503M₩942M₩503Mn/a
EBITDA-₩15.6B-₩10.1B-₩8.04Bn/an/a
Net income-₩12.0B-₩9.01B-₩5.73B-₩22.8B-₩11.4B
Free cash flow-₩11.9B-₩9.16B-₩8.40B-₩5.96B-₩4.60B
Capital expenditure₩1.88B₩1.51B₩2.38B₩327M₩1.25B
Total debt₩728M₩867M₩1.01B₩16.7B₩5.70B

Quarterly statements and history in the cockpit →

PROTEINA competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%0%+20%300289MDXG4549002016603987603309CU6ANGOCEVI300246300110301033688026MOBISI603520REG1V1763468530.KS6-month return →1-month return →
Up and to the right = strong over both horizons. PROTEINA is the large dot.

Fundamentals: return on equity against price-to-book

-75%-50%-25%0%100×200×300289MDXG4549002016CU6ANGOCEVI300110301033688606MOBISIREG1V468530.KSReturn on equity →Price / book →
A bank or insurer earning more on its equity usually trades at a higher multiple of book; points far above the trend are priced for more. PROTEINA is the large dot.

Capital: ROE delivered against the ROE the price implies

-50%0%50%-50%0%50%300289MDXG4549002016CU6ANGOCEVI300110002932SI468530.KSROE delivered →ROE the price implies →
Above the diagonal = the price asks for a higher return on equity than the business earns today. PROTEINA is the large dot.

PROTEINA competitors and peer comparison

How PROTEINA compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

PROTEINA against its 20 peers (data as of 18 Nov 2026)
Measure468530.KSPeer medianRank in peer set
1-month return+24.9%-6.1%2nd highest of 21
6-month return+5.1%-16.2%4th highest of 21
Return on equity-68.1%1.4%3rd lowest of 21
Price / book26.75×2.04×most expensive of 21
ROE the price implies70.0%13.1%most demanding of 21
ROE delivered-68.1%1.5%2nd lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthROEPrice / bookImplied ROEDelivered ROE
PROTEINA 468530.KSSouth Korea$460M+5%-59%-68%26.75×70.0%-68.1%
Beijing Leadman Biochemistry 300289.SZChina$460M-9%+46%-1%1.87×13.9%-0.5%
MiMedx MDXGUnited States$464M-16%-23%-9%2.20×20.4%-8.5%
Eiken Chemical 4549.TJapan$466M-20%+4%4%1.68×10.5%4.2%
Guangdong Shirongzhaoye 002016.SZChina$453M-26%-31%2%0.61×4.7%1.8%
Shanghai Kindly Enterprises Development 603987.SSChina$452M-12%0%8%1.04×9.2%7.9%
WELL LEAD MEDICAL 603309.SSChina$473M-22%+1%2%1.73×9.3%1.8%
Clarity Pharmaceuticals CU6.AXAustralia$444M-33%n/a-78%3.56×44.2%-77.5%
AngioDynamics ANGOUnited States$476M-4%+8%-19%2.93×13.4%-19.2%
CellaVision CEVI.STSweden$477M+64%+2%15%5.20×21.5%15.5%
Guangdong Biolight Meditech 300246.SZChina$478M-35%+7%-10%2.91×18.4%-10.2%
Huaren Pharmaceutical 300110.SZChina$440M-16%-3%-44%3.39×16.6%-44.2%
Medprin Regenerative Medical Technologies 301033.SZChina$482M-14%+23%16%3.71×18.3%15.8%
Hangzhou Alltest Biotech 688606.SSChina$484M-20%0%3%0.82×5.4%3.0%
Guangzhou Jet Bio-Filtration 688026.SSChina$436M+39%+5%2%2.33×22.1%2.0%
Wuhan Easy Diagnosis Biomedicine 002932.SZChina$485M-14%-9%-1%0.55×3.1%-1.2%
Mobia Medical MOBIUnited States$434M+2%+105%-246%2.75×12.8%n/a
Shoulder Innovations SIUnited States$432M+39%+55%-25%3.65×16.0%-25.1%
Zhejiang Starry Pharmaceutical 603520.SSChina$491M-44%+9%1%1.33×11.8%1.1%
Revenio REG1V.HEFinland$428M-34%+44%9%1.74×11.5%9.1%
China Isotope & Radiation 1763.HKHong Kong$428M-41%-5%6%0.58×5.9%n/a

Questions

Which companies are PROTEINA's closest peers?
The cockpit's peer set: Beijing Leadman Biochemistry (300289.SZ), MiMedx (MDXG), Eiken Chemical (4549.T), Guangdong Shirongzhaoye (002016.SZ), Shanghai Kindly Enterprises Development (603987.SS), WELL LEAD MEDICAL (603309.SS), Clarity Pharmaceuticals (CU6.AX), AngioDynamics (ANGO).
Is PROTEINA expensive compared with its peers?
On price / book it trades at 26.75× against a peer median of 2.04×, most expensive of 21 in its peer set. The share price implies a return on equity of about 70.0%; PROTEINA delivers -68.1%, so the price asks more than the business earns today.
How has PROTEINA stock performed?
Over six months to 18 Nov 2026 the shares returned +5.1% against -16.2% for the median peer; over one year -16.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.